Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010

  • Jacques Pépin ,

    Affiliation Department of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, Québec, Canada

  • Claire Nour Abou Chakra,

    Affiliation Department of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, Québec, Canada

  • Eric Pépin,

    Affiliation Department of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, Québec, Canada

  • Vincent Nault,

    Affiliation Department of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, Québec, Canada

  • Louis Valiquette

    Affiliation Department of Microbiology and Infectious Diseases, Université de Sherbrooke, Sherbrooke, Québec, Canada

Evolution of the Global Burden of Viral Infections from Unsafe Medical Injections, 2000–2010

  • Jacques Pépin, 
  • Claire Nour Abou Chakra, 
  • Eric Pépin, 
  • Vincent Nault, 
  • Louis Valiquette



In 2000, the World Health Organization estimated that, in developing and transitional countries, unsafe injections accounted for respectively 5%, 32% and 40% of new infections with HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). Safe injection campaigns were organized worldwide. The present study sought to measure the progress in reducing the transmission of these viruses through unsafe injections over the subsequent decade.


A mass action model was updated, to recalculate the number of injection-related HIV, HCV and HBV infections acquired in 2000 and provide estimates for 2010. Data about the annual number of unsafe injections were updated. HIV prevalence in various regions in 2000 and 2010 were calculated from UNAIDS data. The ratio of HIV prevalence in healthcare settings compared to the general population was estimated from a literature review. Improved regional estimates of the prevalence of HCV seropositivity, HBsAg and HBeAg antigenemia were used for 2000 and 2010. For HIV and HCV, revised estimates of the probability of transmission per episode of unsafe injection were used, with low and high values allowing sensitivity analyses.


Despite a 13% population growth, there was a reduction of respectively 87% and 83% in the absolute numbers of HIV and HCV infections transmitted through injections. For HBV, the reduction was more marked (91%) due to the additional impact of vaccination. While injections-related cases had accounted for 4.6%–9.1% of newly acquired HIV infections in 2000, this proportion decreased to 0.7%–1.3% in 2010, when unsafe injections caused between 16,939 and 33,877 HIV infections, between 157,592 and 315,120 HCV infections, and 1,679,745 HBV infections.


From 2000 to 2010, substantial progress was made in reducing the burden of HIV, HCV and HBV infections transmitted through injections. In some regions, their elimination might become a reasonable public health goal.


Injections made with a syringe and/or a needle previously used on another patient carry a risk of transmission of blood-borne viruses when equipment is re-used without adequate sterilization and correspond to an overwhelming majority of ‘unsafe injections', while use of multi-dose medication vials represents a smaller part of the problem. In 2000, the World Health Organization (WHO) estimated that, in developing and transitional countries, unsafe injections accounted for 5% of new HIV infections, 32% of new hepatitis B virus (HBV) infections and 40% of new hepatitis C virus (HCV) infections [1][3]. These estimates were based on a mass action model, in which the incidence of each blood-borne virus acquired from unsafe injections, ‘Iu’, is a product of the size of the susceptible population, ‘ps’ (those not yet infected and, in the case of HBV, not yet vaccinated), the probability of transmission during an unsafe injection, ‘pt’, the probability that injection equipment is re-used, ‘pr’, the prevalence of the infection in the population, ‘pv’, and the number of injections performed per person-year, ‘n’, as follows: Iu  =  ps * [1-(1- pt * pr * pv)n].

Since then, the Safe Infection Global Network, ministries of health and other stakeholders have attempted to reduce the infectious risks associated with injections [4]. We reported elsewhere the changes from 2000 to 2010 in the number of unsafe injections per person-year, which decreased from 1.35 to 0.16 [5]. Here we attempted to quantify the evolution of the number of cases of injections-related HIV, HCV and HBV infections during that period. We first sought to recalculate the number of injection-related infections in 2000, using the same model but altering some parameters based on relevant information which has accrued since the previous work, and then we calculated the same outcomes for 2010, using updated epidemiological data. To allow comparisons, regions as defined in the 2000 Global Burden of Diseases (GBD) study were used (Table 1), excluding four high-income regions where unsafe injections are thought to be uncommon (North America/Cuba, Western Europe, Japan/Australia/New Zealand and other developed countries mostly in the Middle East) [1][3].

Table 1. Regions of the world (developing and transitional economies) as defined during the 2000 Global Burden of Diseases study.


Number of unsafe injections per person per year

No change was made in the average number of unsafe injections per person per year in 2000 [1][3]. For 2010, in several regions there were reductions in unsafe injections, mostly through a lower proportion of re-use, and these figures were used for all three blood-borne viruses [5]. Given the lack of injections data for the three countries that constituted region SEAR B, extrapolations were made from India, Vietnam and Cambodia. Population figures were updated [6]. Changes in parameters specific for each virus are described below.

Revised estimate of the probability of transmission per unsafe healthcare injection, pt

The probability of transmission of HIV, HCV and HBV per episode of unsafe healthcare injection cannot be measured directly, so that two proxies must be used: the risk of transmission during a needle stick injury in healthcare workers (HCW) and the risk of transmission per episode of needle/syringe sharing by injection drug users (IDU).

For HCV, the ‘pt’ for HCW injuries previously used (1.8%), generally accepted at the time, was overestimated because early studies had used unreliable diagnostic assays. A review published in 2002 estimated this ‘pt’ at 0.5% (59 infections after 11324 injuries) [7]. For HIV, the ‘pt’ for HCW injuries is generally estimated to be 0.32%, based on follow-up after 6202 exposures [8][12]. A 2006 meta-analysis estimated this risk at 0.24% [13]. The risk of transmission of HIV per episode of sharing of needles and/or syringes was estimated at between 0.63% and 1.57% [14][16].

When comparing unsafe injections to needle stick injuries, competing factors must be considered. Actions associated with an injection (inserting a needle deep into a muscle, and pushing its content with the plunger) may enhance the risk compared to HCW injuries, which are generally superficial. But on the other hand, one third of HCW injuries occur after a needle had been placed in the patient's vein (to draw blood, to insert an intravenous line, etc.) [17][18]. Most healthcare injections being made intramuscularly or subcutaneously, the amount of blood from the index patient that ends up in the needle/syringe is lower than when a HCW manipulated a needle deliberately inserted into a patient's vein. Furthermore, the ‘pt’ during unsafe injections must be lower than in IDU, among whom the potential transfer of viruses occurs from vein to vein.

Thus, the ‘pt’ of HIV (1.2%) and HCV (1.8%) per episode of contaminated healthcare injection used for 2000 were presumably overestimated [1], [3]. It is more prudent to use, for each virus, a low estimate, corresponding to the probability of transmission during a needle stick injury to a HCW, and a high estimate which probably should be not more than double the low one. For HIV, this corresponds to 0.32% and 0.64%, nearly identical to the 0.24%–0.65% proposed elsewhere in a meta-analysis [13], our high value for medical injections being close to the lower estimates (0.63%) of the transmission risk among IDU. For HCV, the same approach yields values of 0.5% and 1.0%.

The probability of HBV transmission during an unsafe injection had been assumed to be 6% for HBeAg-negative source patients and 30% for HBeAg-positive patients, in line with other estimates, and we used the same values given that this has not been studied further in recent years [1], [3], [19], [20]. However, it had been arbitrarily assumed that in most regions 20% of the HBsAg-positive individuals were HBeAg-positive, yielding an overall pt = 10.8%, while elsewhere 50% were HBeAg-positive, for an overall pt = 18% [1], [3]. We rather calculated region-specific values of ‘pt’, based on estimates of the proportion of HBeAg antigenemic individuals.

Revised estimates of HIV prevalence in 2000 and estimates for 2010

UNAIDS revised retrospectively its measures of national HIV prevalence when Demographic and Health Surveys (DHS), with HIV testing on capillary blood, revealed that in several countries the prevalence (previously measured through surveys of pregnant women) had been overestimated because of an under-sampling of rural populations and an overestimate of the prevalence in men [21], [22]. The regional estimates of HIV prevalence for 2000 were recalculated, and those for 2010 were calculated the same way. From UNAIDS data for 2001 (revised figures) and 2009 [21], we extrapolated to 2000 and 2010, based on the mean annual changes in prevalence. Assuming that in most primary care settings children and adults are treated with the same pool of needles and syringes, the overall prevalence was calculated (and not merely among those aged 15–49 years).

Estimation of HIV prevalence in healthcare settings

Previous calculations had used the HIV prevalence in the general population and assumed that prevalence among patients attending healthcare facilities was the same [1], [3]. However, HIV-infected patients develop symptoms for which they seek care and receive injections. Consequently, in certain healthcare settings, for instance patients hospitalized in a medical ward, the HIV prevalence is much higher than in the general population, as pointed out by Reid [23]. That effect, although less marked, is also present in primary care settings, even if a substantial fraction of their caseload corresponds to children, because HIV-infected children are also more likely to attend outpatient services than the seronegatives. Furthermore, in some primary care centers a substantial fraction of the caseload consists of patients with sexually transmitted infections, further enhancing HIV prevalence.

Furthermore, the propensity of HIV-infected patients to attend a health facility increases as the disease progresses and so does their viremia, hence their infectiousness. We assumed that this latter phenomenon was intrinsically tailored in within the estimates of the efficacy of transmission to HCW, and no further adjustments were made.

We reasoned that, worldwide, most injections (and most unsafe injections) are given to outpatients in primary care facilities: for-profit clinics (operated by physicians, nurses or unqualified personnel), governmental health centers, facilities run by non-profit organizations, outpatient departments of hospitals, etc. We assumed that, with regard to the syringes/needles used, patients treated in such facilities represent a single population (a mix of children and adults), rather than two distinct compartments each with their own pool of syringes/needles.

To identify relevant studies, Medline searches were performed (Appendix S1) and the US Census Bureau database was searched [24], seeking reports about patients in healthcare settings in developing/transitional countries published since 1995. The goal being to obtain measures of HIV prevalence among unselected, consecutive patients attending healthcare facilities, studies that represented obvious biases one way or the other were excluded, for instance measures among: i) inpatients, in which the HIV-infected would be much over-represented compared to outpatient settings; ii) patients presenting with conditions strongly associated with HIV infection (tuberculosis, pneumonia, etc.); iii) patients attending sexually transmitted diseases clinics or facilities for voluntary testing where the HIV-infected are over-represented; iv) antenatal clinic attendees and blood donors, since these visits are not prompted by ongoing symptoms. Furthermore, were excluded studies where the HIV status had been determined by a single test, studies with fewer than 200 participants, or with unavailable full text.

A total of 4052 titles and abstracts were scanned for full-text review and potential inclusion. Ultimately, 16 studies fulfilled all of the inclusion criteria and presented no exclusion criterion [25][41]. These measures of healthcare prevalence were compared with measures of HIV prevalence in the population of the same city or region. In some locations, this was possible through a DHS measure [22]. The prevalence in men and women combined was used, except for an all-women study in Uganda [34] for which the female prevalence was used as comparator. When the study population had been limited to some age groups the prevalence in age groups as close as possible was used as comparator. The comparator prevalence was adjusted for the interval that had elapsed between the study and the corresponding DHS, based on estimates for the variation in HIV prevalence between 2001 and 2009 [19]. For the paediatric studies, regional estimates made by the South African Department of Health for children aged 2–14 years were used as comparator [41]. For the other studies, our comparator prevalence was based on surveys of HIV among antenatal clinic attendees of the same location [24], generally available for the same year as the study itself. To translate this into a prevalence for the whole adult population, an adjustment took into consideration differences in prevalence between men and women, based on UNAIDS estimates in that particular country [21].

Novel information on the prevalence of HCV and HBV in each region

Researchers recently estimated the prevalence of HCV seropositivity and HBsAg antigenemia in various regions in 1990 and 2005, for each sex and age stratum, based on a review of respectively 232 and 396 scientific papers and mathematical modelling [42], [43]. These estimates seemed more evidence-based than the empirical ones previously used [1][3]. We calculated the annual variation in the prevalence of HCV seropositivity and HBsAg antigenemia between 1990 and 2005, to extrapolate the prevalence in 2000 and 2010. To calculate the overall regional prevalence, the populations of each age stratum were used as weights [6]. As the data for 1990 and 2005 were presented along a revised classification of countries (GBD 2010), the latter was converted into prevalence for GBD 2000 regions, according to the proportions of each 2000 region that came from each 2010 region. No adjustment was made for a potentially higher prevalence in healthcare settings, which seems unlikely given that only a minority of HCV-infected and HBV-infected persons develop cirrhosis.

A similar exercise measured, in each region, the proportion of HBsAg-positive individuals who are HBeAg-positive, based on fewer publications [44]. Prevalence of HBeAg antigenemia among HBsAg-positive individuals was much higher in young children and decreased steadily with older age; geographic variations were modest.

In many low-income countries, HBV vaccine was introduced into the immunisation programme during the 2000–2010 decade, and the fraction of recipients of unsafe injections susceptible to iatrogenic HBV infection decreased progressively among children and adolescents. The proportions of the population of various age groups deemed non-susceptible through vaccination or natural infection were not altered for 2000, but had to be corrected for 2010. WHO collates data provided by member states concerning the proportion of infants who have received the third dose of HBV vaccine by the age of 12 months [45]. For each country, immunisation rates were calculated for two age strata, 0-4 years and 5–14 years, and translated into proportions of susceptibility (‘ps’) to HBV infection for each region, allowing for natural infections as well. For individuals older than 14 years, the same ‘ps’ as in the 2000 model [1], [3] were used.


HIV prevalence

The revisions in HIV prevalence in the overall population had only a modest impact on the estimated regional prevalence for 2000 [1], [3]. For the prevalence in healthcare settings, thirteen studies contained data about adults, two presented paediatric data, and one had included both children and adults. Most studies had been performed in Africa, two in India and one in Haiti. HIV prevalence among study populations varied widely. The ratio between the prevalence among patients attending a healthcare facility and that in the comparator in each of 16 studies is shown in Supporting Information, Table S1. The means of these ratios was 2.48 for studies with adults, 2.69 for the paediatric studies, and 2.52 overall. This latter figure was multiplied by the prevalence in the overall population to derive the prevalence in healthcare settings, for each region, in 2000 and 2010 (Table 2). In 2010, this prevalence decreased in AFR E, and increased in EMR D and EUR C.

Table 2. Estimates of HIV prevalence (%) in the overall population and in healthcare settings, in 2000 and 2010.

Hepatitis C prevalence

The revised estimates of regional prevalence of HCV seropositivity for 2000 are displayed in Table 3 along with the data for 2010. Compared to the previously used data [1], [3], there was relatively little change in regional HCV prevalence for 2000. In 2010, prevalence increased in six regions.

Hepatitis B prevalence

The revised estimates of regional prevalence of HBsAg and HBeAg for 2000 are shown in Table 4. For the high-prevalence regions, the revised estimates of prevalence of HBsAg antigenemia were lower than before [1]. The revised proportions of the HBsAg-positives who were HBeAg antigenemic in 2000 were generally higher than in the original model, except for the two regions where this prevalence had been arbitrarily estimated at 50%. Since HBeAg antigenemia has a profound influence on the ‘pt’ for HBV, the regional ‘pt’ varied accordingly. Table 4 also displays the data for 2010. In all but one region, the prevalence of HBsAg antigenemia decreased. There was a modest reduction in the proportion of HBsAg-positive individuals who were HBeAg antigenemic.

Table 4. Prevalence (%) of HBsAg and HBeAg antigenemia, in 2000 and 2010.

Estimates of HIV infections transmitted through unsafe injections in 2000 and 2010

Table 5 shows the revised estimates of HIV infections transmitted through unsafe injections in 2000, based on the same model but with HIV prevalence in health care settings as ‘pv’ and with the two revised ‘pt’ values. Our higher estimate for 2000, based on pt = 0.64%, yielded estimates similar to those presented initially [1], [3], with roughly a quarter of a million HIV infections acquired through unsafe injections. Naturally, the estimates with pt = 0.32% yielded figures that were half the other measure. Based on previously mentioned assumptions, between 133,328 and 266,405 HIV infections were acquired worldwide through unsterile injections in 2000. Region SEAR D (mostly India) had represented more than half of the global number of injections-related cases of HIV, to a large extent because it was estimated that 75% of injections in SEAR D were made with re-used needles and syringes, based on a survey in India [1][3]. Despite a much higher ‘pv’, the contribution of sub-Saharan Africa was lower than SEAR D, because of fewer injections and less frequent re-use. Using UNAIDS revised data as denominators, in developing and transitional economies, between 4.6% and 9.1% of all new HIV infections in 2000 were caused by unsafe injections [21].

Table 5. HIV infections transmitted through unsafe injections, in 2000 and 2010.

For 2010, the main changes in parameters were in the number of unsafe injections per person per year [5] and the HIV prevalence in healthcare settings. The same two values of ‘pt’ were used. Between 16,939 and 33,877 HIV infections were acquired through unsafe injections worldwide (Table 5). Sub-Saharan Africa represented 48% of such cases, while the contribution of SEAR D decreased to 18%. Compared to 2000, the number of injections-related HIV infections acquired worldwide decreased by 87% in 2010, when between 0.7% and 1.3% of all new HIV infections were so acquired [21].

Estimates of HCV infections transmitted through unsafe injections in 2000 and 2010

Table 6 shows the revised estimates of HCV infections transmitted through unsafe injections in 2000, based on the revised measures of prevalence and the two values of ‘pt’. We estimated that in 2000 between 952,111 and 1,867,904 HCV infections were injections-related. Again, the higher estimate for all ten regions was similar to the one generated previously [1], [3], even if the regional distribution varied. Table 6 also displays the results for 2010, using the same ‘pt’ values, the updated regional prevalence and the updated numbers of unsafe injections [5]. In 2010, between 157,592 and 315,120 HCV infections were acquired from unsafe injections, about one third of which occurred in EMR D and another third in WPR B.

Table 6. HCV infections transmitted through unsafe injections, in 2000 and 2010.

Estimates of HBV infections transmitted through unsafe injections in 2000 and 2010

Table 7 displays the estimates of HBV infections transmitted through unsafe injections in 2000, using the same HBeAg-specific values of ‘pt’ applied on the revised estimates of the prevalence of HBsAg and HBeAg antigenemia. Although the regional figures varied along with modifications in the prevalence of antigenemia, the total for all ten regions was again similar to the one calculated previously for 2000, with 19,710,444 HBV infections acquired from injections. Table 7 also shows the results for 2010, based on the same values of ‘pt’ and the updated estimates of the number of unsafe injections and of the prevalence of HBsAg and HBeAg antigenemia in 2010 [5]. Compared to 2000, there was a 91% reduction in the number of injections-related HBV infections, to 1,679,745 new infections.

Table 7. HBV infections transmitted through unsafe injections, in 2000 and 2010.


The main finding of this study is that, between 2000 and 2010, there has been a reduction of respectively 87% and 83% in the estimated number of cases of HIV and HCV infections transmitted through unsafe injections. In the case of HBV, the reduction was more marked (91%) due to the additional impact of the rolling out of vaccination in most of the world.

We used the mathematical model developed previously [1], [3], because the main goal was to measure the relative reduction (2010 versus 2000) in injections-related HIV, HCV and HBV infections, but also because this model did not seem to be flawed, even if by definition all models are imperfect. A number of decisions about how to use it could be debated, however. First, random mixing between all age groups was assumed. That probably occurs in most private outpatient facilities, but less so in large hospitals. What proportion of injections worldwide is made through two distinct compartments, one for children and the other for adults remains unknown. Second, in our calculation of the relative prevalence of HIV in healthcare settings, inpatients data were excluded, lowering this estimate. What proportion of injections worldwide is given to outpatients versus inpatients remains unclear, and there might be a better compliance with single-use syringes and needles in hospital settings. Third, the values of ‘pt’ could be endlessly debated. Some authors argue that this probability is much higher than the values that we used [23], [47], but it does not seem plausible that transmission could be several fold more common during IM or SC unsafe medical injections than through IV injections of recreational drugs among addicts. Finally, potential biases in the measures of unsafe injections have been discussed elsewhere [5]. Apart from the latter, these sources of imprecision would be expected to have little impact on the measures of the relative reduction in the iatrogenic transmission of viruses over time.

Given that sampling variation and other imprecisions existed at various degrees for the five parameters used in the model, it was not possible to calculate confidence intervals around the absolute number of infections, and we elected to rather present sensitivity analyses for HIV and HCV based on two values of ‘pt’, the one parameter for which there was no direct measurement. HBV transmission during needle stick injuries has been little studied during the last 30 years using modern serological assays, precluding meaningful sensitivity analyses. In the future, model-based estimates could be complemented by the inclusion of children within the DHS of some countries, allowing a measurement of relatively recent non-sexual transmission of HIV and HCV, and of natural infections with HBV.

Of the three blood-borne viruses evaluated in the current study, HIV generally elicits most controversy [23], [46], [47]. There are reasons to believe that the revised measures for 2000 are improved compared to the prior version [1], [3]. The HIV prevalence in various regions of the world is better defined because it is now based, in many countries, on surveys of a representative sample of the nation's population. For the first time, an attempt was made to measure the relative prevalence of HIV in healthcare settings. And it seems likely that the two measures of ‘pt’, 0.32% and 0.64%, which now provide a sensitivity analysis, would be accepted by most experts. Ultimately, the number of injections-related HIV infections estimated previously for 2000 (256,152) [1], [3] was similar to our higher figure (266,405, if pt = 0.64%), while our low estimate (133,328, if pt = 0.32%) represented half of that measure. Despite the 13% population growth, the number of injections-related HIV infections decreased to only 16,939–33,877 in 2010, a remarkable public health achievement, and the fraction of new cases of HIV infection acquired through unsafe injections decreased to 0.7%–1.3% of the worldwide total of new infections in 2010, compared to 4.6%–9.1% ten years earlier. Most of this was driven by the reduction in the average number of unsafe injections, but decreasing HIV prevalence also impacted favourably in East and Southern Africa. We did not attempt to model the effect of the deployment of antiretrovirals on ‘pt’. This may need to be considered in the future, as the suppression of viremia lowers infectiousness but on the other hand prolongs survival, hence the duration of infectiousness.

The number of cases of HCV infections acquired from unsafe injections also declined substantially. Again our high estimate for 2000 was similar to the previous one [1], [3]. By 2010, the number of HCV infections from unsterile injections had dropped by 83%. The effect of the reduction in unsafe injections was attenuated by the population growth and the increasing prevalence in some densely populated regions [1][3]. The latter changes in HCV prevalence are likely multi-factorial: incomplete screening of blood donors, ongoing transmission among IDUs, and persistent transmission by parenteral modes other than injections. The long-term survival of most HCV-seropositive individuals also impacts on prevalence.

The progress with injections-related HBV infections was even more marked, at 91%. Several factors, attenuated only by the population growth, led to this reduction: fewer unsafe injections, lower prevalence of HBsAg and HBeAg antigenemia, and lower susceptibility to HBV through vaccination. Independently of any further progress in injection safety, this trend will continue as the immunised cohorts get older, producing direct and indirect effects. And as the HBsAg-positive subpopulation ages, it is also less prone to be HBeAg antigenemic, further reducing transmission.

Given this progress, the cost per additional case of injections-related HIV, HCV and HBV infections averted will increase, as is true for all disease control initiatives. We argue that these efforts should be maintained or expanded, even if more expensive, for two reasons. First, a moral imperative: iatrogenic infections with HIV, HCV and HBV are unacceptable, and go against a Hippocratic principle: ‘first, do no harm'. Second, as treatments against HIV and HCV are increasingly deployed in developing countries and transitional economies, incremental funding for the prevention of the remaining iatrogenic infections may generate savings. Elimination of these risks could become a reasonable goal in sub-Saharan Africa and Latin America. Such an achievement in Africa could remove half of the remaining burden of injections-related HIV infections worldwide.

However, other modes of iatrogenic transmission of blood-borne viruses, not covered by the current work, persist and will need to be addressed in the future. For instance, use of multi-dose medication vials, phlebotomies with re-used needles, dental care with improper sterilisation of instruments, unscreened transfusions, ritual scarifications and circumcisions performed by traditional practitioners all continue unabated, and should be included within ongoing efforts to reduce infectious risks for patients worldwide. Better measurement of such exposures and of their impact on viral dynamics is an essential first step, and the inclusion of children within demographic and health surveys could provide much needed data.

Supporting Information

Table S1.

Estimation of the ratio of HIV prevalence in healthcare settings compared to the general population.



Appendix S1.

Strategies to identify relevant publications for the comparison of HIV prevalence in healthcare setting with that of the general population.




We are indebted to Yvan Hutin for his helpful comments and suggestions.

Author Contributions

Conceived and designed the experiments: JP. Performed the experiments: JP CNAC EP VN LV. Analyzed the data: JP CNAC EP VN LV. Contributed reagents/materials/analysis tools: CNAC EP VN LV. Wrote the paper: JP CNAC EP VN LV.


  1. 1. Hauri AM, Armstrong GL, Hutin YJF (2004) The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 16: 7–16.
  2. 2. Hutin YJF, Hauri AM, Armstrong GL (2003) Use of injections in healthcare settings worldwide, 2000; literature review and regional estimates. BMJ 323: 1075.
  3. 3. Hauri AJ, Armstrong GL, Hutin YJF (2004) Contaminated injections in health care settings. In: M Ezzati, et al.. editors. Comparative quantification of health risks. Geneva, World Health Organization.
  4. 4. The SIGN Alliance. Available: Accessed 2014 April 25.
  5. 5. Pepin J, Abou Chakra CN, Pepin E, Nault V (2013) Evolution of the global burden of unsafe medical injections, 2000–2010. PLoS One 2013;e80948.
  6. 6. United Nations Department of Economic and Social Affairs. World Population Prospects, the 2010 revision. Available: Accessed 2014 April 25.
  7. 7. Jagger J, Puro V, De Carli G (2002) Occupational transmission of Hepatitis C virus. JAMA 288: 1469–1470.
  8. 8. Centers for Disease Control and Prevention (2001) Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for post-exposure prophylaxis. Morb Mort Wkly Rep 50 (RR-11): 1–52.
  9. 9. Gerberding JL (2003) Occupational exposure to HIV in healthcare settings. N Engl J Med 348: 826–833.
  10. 10. Bell DM (1997) Occupational risk of HIV infections in healthcare workers: an overview. Am J Med 102 (Suppl 5B)9–15.
  11. 11. Tokars JI, Marcus R, Culver DH, Schable CA, McKibben PS, et al. (1993) Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Int Med 118: 913–919.
  12. 12. Ippolito G, Puro V, De Carli G (1993) The risk of occupational HIV infection among healthcare workers: Italian Multicenter Study. Arch Int Med 153: 1451–1458.
  13. 13. Baggaley RF, Boily MC, White RG, Alary M (2006) Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 20: 805–812.
  14. 14. Kaplan EH, Heimer R (1992) A model-based estimate of HIV-1 infectivity via needle sharing. J Acq Immun Def Syndr 5: 1116–1118.
  15. 15. Hudgens MG, Longini IM, Halloran ME, Choopanya K, Vanichseni S, et al. (2001) Estimating the HIV-1 transmission probability in injecting drug users in Thailand. Appl Stat 50: 1–14.
  16. 16. Hudgens MG, Longini IM, Vanichseni S, Hu DJ, Kitayaporn D, et al. (2002) Subtype specific transmission probabilities for HIV-1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol 155: 159–168.
  17. 17. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, et al. (1997) A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 337: 1485–1490.
  18. 18. Yazdanpanah Y, De Carli G, Migueres B, Lot F, Campins M, et al. (2005) Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis 41: 1423–1430.
  19. 19. Gerberding JL (1995) Management of occupational exposures to blood-borne viruses. N Eng J Med 332: 444–451.
  20. 20. Werner BG, Grady GF (1982) Accidental Hepatitis B –surface antigen positive inoculations: use of e antigen to estimate infectivity. Ann Intern Med 97: 367–369.
  21. 21. UNAIDS (2010) UNAIDS report on the global AIDS epidemic. Geneva, UNAIDS.
  22. 22. Measure DHS. Demographic and Health Surveys. Available: Accessed 2014 April 25.
  23. 23. Reid S (2009) Increase in clinical prevalence of AIDS implies increase in unsafe medical injections. Int J STD AIDS 20: 295–299.
  24. 24. United States Census Bureau. HIV AIDS Surveillance Data Base. Available: Accessed 2014 April 25.
  25. 25. Njobvu P, McGill P, Kerr H, Jellis J, Pobee J (1998) Spondyloarthropathy and human immunodeficiency virus infection in Zambia. J Rheumatol 25: 1553–1559.
  26. 26. La Ruche G, You B, Mensah-Ado I, Bergeron C, Montcho C, et al. (1998) Human papillomavirus and human immunodeficiency virus infections: relation with cervical dysplasia-neoplasia in African women. Int J Cancer 76: 480–486.
  27. 27. Tharyan P, Ramalingam S, Kannangai R, Sridharan G, Muliyil J, et al. (2003) Prevalence of HIV infection in psychiatric patients attending a general hospital in Tamil Nadu, south India. AIDS Care 15: 197–205.
  28. 28. Chang LW, Osei-Kwasi M, Boakye D, Aidoo S, Hagy A, et al. (2002) HIV-1 and HIV-2 seroprevalence and risk factors among hospital outpatients in the Eastern Region of Ghana, West Africa. J Acquir Immune Defic Syndr 29: 511–516.
  29. 29. Solomon SS, Pulimi S, Rodriguez II, Chaguturu SK, Satish Kumar SK, et al. (2004) Dried blood spots are an acceptable and useful HIV surveillance tool in a remote developing world setting. Int J STD AIDS 15: 658–661.
  30. 30. Francesconi P, Fabiani M, Dente MG, Lukwiya M, Okwey R, et al. (2001) HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS 15: 2445–2450.
  31. 31. Pilcher CD, Price MA, Hoffman IF, Galvin S, Martinson FEA, et al. (2004) Frequent detection of acute primary HIV infection in men in Malawi. AIDS 18: 517–524.
  32. 32. Croce F, Fedeli P, Dahoma M, Deho L, Ramsan M, et al. (2007) Risk factors for HIV/AIDS in a low HIV prevalence site of sub-Saharan Africa. Trop Med Int Health 12: 1011–1017.
  33. 33. Kamya MR, Gasasira AF, Yeka A, Bakyaita N, Nsobya SL, et al. (2006) Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 193: 9–15.
  34. 34. Banura C, Francheschi S, van Doorn LJ, Arslan A, Wabwire-Mangen F, et al. (2008) Infection with human papillomavirus and HIV among young women in Kampala, Uganda. J Infect Dis 197: 555–562.
  35. 35. Ivers LC, Freedberg KA, Mukherjee JS (2007) Provider-initiated HIV testing in rural Haiti: low rate of missed opportunities for diagnosis of HIV in a primary care clinic. AIDS Res Ther 4: 28.
  36. 36. Van Geertruyden JP, Mulenga M, Mwananyanda L, Chalwe V, Moerman F, et al. (2006) HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 194: 917–925.
  37. 37. Wanyenze RK, Nawavvu C, Namale AS, Mayanja B, Bunnell R, et al. (2008) Acceptability of routine HIV counselling and testing, and HIV seroprevalence in Ugandan hospitals. Bull World Health Organ 86: 302–309.
  38. 38. Bebell LM, Pilcher CD, Dorsey G, Havlir D, Kamya MR, et al. (2010) Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria. AIDS 24: 1945–1952.
  39. 39. Shisana O, Connolly C, Rehle TM, Mehtar S, Dana P (2008) HIV risk exposure among South African children in public health facilities. AIDS Care 20: 755–763.
  40. 40. Horwood C, Butler LM, Vermaak K, Rollins N, Haskins L, et al. (2011) Disease profile of children under 5 years attending primary health care clinics in a high HIV prevalence setting in South Africa. Trop Med Int Health 16: 42–52.
  41. 41. Avert. South Africa HIV & AIDS statistics. Available: Accessed 2013 December 1.
  42. 42. Hanafiah KH, Groeger J, Flaxman AD, Wiersma ST, et al. (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence. Hepatology doi:10.1002/hep.26141.
  43. 43. Ott JJ, Stevens GA, Groeger J, Wiersma ST (2012) Global epidemiology of Hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 2212–2219.
  44. 44. Ott JJ, Stevens GA, Wiersma ST (2012) The risk of perinatal Hepatitis B virus transmission. Hepatits B e Antigen (HBeAg) prevalence estimates for all regions of the world regions. BMC Infect Dis 12: 131.
  45. 45. World Health Organization. Immunization surveillance, assessment and monitoring. Available: Accessed 2014 April 25.
  46. 46. Schmid GP, Buvé A, Mugyenyi P, Garnett GP, Hayes RJ, et al. (2004) Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. Lancet 363: 882–888.
  47. 47. Gisselquist D, Upham G, Potterat JJ (2006) Efficiency of Human Immunodeficiency Virus transmission through injections and other medical procedures: evidence, estimates, and unfinished business. Infect Control Hosp Epidemiol 27: 944–952.